Top Markets
#1 DogBull DogBull +53.24%
#2 OriginTrail OriginTrail +14.59%
#3 Verus Coin Verus Coin +11.27%
#4 龙虾 (Lobster) 龙虾 (Lobster) +10.66%
#5 Siren Siren +10.57%
#6 Stargate Finance Stargate Finance +6.74%
#7 Tutorial Tutorial +6.70%
#8 Cysic Cysic +6.63%
#9 COTI COTI +6.27%
#10 LayerZero LayerZero +6.03%
Coin of the day
DogBull DogBull
Instellingen
Taal
DUTCH
Valuta
USD
Thema
3D Medicines Inc. 3D Medicines Inc.

3D Medicines Inc.

1244
Rang in aandelen #22092
Established in 2014 and headquartered in Qingdao, China, 3D Medicines Inc. is a... Established in 2014 and headquartered in Qingdao, China, 3D Medicines Inc. is a biopharmaceutical company dedicated to the discovery, development, and market introduction of innovative oncology drugs and therapeutic candidates. Its core mission is to address diverse cancer types, primarily serving patients in Mainland China. The company's flagship product, Envafolimab, is a PD-L1 antibody administered via subcutaneous injection. This treatment is approved for advanced solid tumors characterized by microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) status in patients who have undergone previous therapies. Beyond its currently marketed drug, 3D Medicines boasts a robust development pipeline. Two significant candidates are currently undergoing Phase III clinical trials: 3D189, which targets multiple tumor indications, and 3D229 (a GAS6/AXL inhibitor), under investigation for non-small cell lung cancer, ovarian cancer, and kidney cancer. The company's Phase II pipeline includes 3D1001, designed to manage postoperative dental pain and tumor-related discomfort, and 3D1002, also aimed at oncology pain relief. Additionally, 3D185 is in Phase I clinical evaluation for locally advanced or metastatic solid tumors. Further promising candidates in earlier stages encompass 3D197 for multi-indication tumor immunotherapy, 3D011 for advanced malignant solid tumors, and 3D057 for various types of tumors.
Aandeelprijs
$0.38441832
Laatst gesynchroniseerd: 2026-08-21
Marktkapitalisatie
$94.54M
Verandering (1 dag)
-12.13%
Verandering (1 jaar)
-62.78%
Land
CN
Handel 3D Medicines Inc. (1244)

Categorie

Healthcare
Dividendgeschiedenis van 3D Medicines Inc. (1244)
3D Medicines Inc. (aandelsymbool: 1244) heeft in totaal 0 dividenduitkeringen gedaan.
De som van alle dividenden (aangepast voor aandelensplitsingen) is: 0.00
Dividendrendement (TTM): 0
Dividendbetalingen voor 3D Medicines Inc. (1244) van 2026 tot 2026
Jaarlijkse dividendbetalingen
Jaar Dividend (aangepast voor aandelensplitsingen) Wijzigen
Niet genoeg gegevens voor de verstrekte datums.
Lijst van alle dividendbetalingen
Jaar Dividend Wijzigen
Niet genoeg gegevens voor de verstrekte datums.
Dividendbetalingen voor vergelijkbare bedrijven of concurrenten
Bedrijf Aantal dividendbetalingen Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
0.00%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
0.00%
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
0.00%
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
64.00%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
0.00%
CH